Journal
NEUROPSYCHIATRIC DISEASE AND TREATMENT
Volume 10, Issue -, Pages 1103-1111Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/NDT.S64236
Keywords
schizophrenia; minocycline; microglia; neuroinflammation
Categories
Funding
- National Natural Science Foundation of China [81071093]
Ask authors/readers for more resources
Accumulating evidence suggests that neuroinflammation affecting microglia plays an important role in the etiology of schizophrenia, and appropriate control of microglial activation may be a promising therapeutic strategy for schizophrenia. Minocycline, a second-generation tetracycline that inhibits microglial activation, has been shown to have a neuroprotective effect in various models of neurodegenerative disease, including anti-inflammatory, antioxidant, and antiapoptotic properties, and an ability to modulate glutamate-induced excitotoxicity. Given that these mechanisms overlap with neuropathologic pathways, minocycline may have a potential role in the adjuvant treatment of schizophrenia, and improve its negative symptoms. Here, we review the relevant studies of minocycline, ranging from preclinical research to human clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available